
Isomorphic Labs announces $5B Series C for drug design and clinical preparation (opens in a new tab)
Isomorphic Labs says its November 17 Series C was co-led by Greenoaks and Sequoia Capital. Funds will support IsoDDE, drug candidates and R&D infrastructure. Reported positive results are largely preclinical; human safety and efficacy still need validation.


















